Litcius/Paper detail

A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple <i>Clostridioides difficile</i> Infection Recurrences

Andrew M Skinner, Xing Tan, Benjamin D Sirbu, Larry H. Danziger, Dale N. Gerding, Stuart Johnson

2021Clinical Infectious Diseases17 citationsDOI

Abstract

We treated 46 patients with multiple recurrent Clostridioides difficile infections (mrCDI) using a tapered-pulsed (T-P) fidaxomicin regimen, the majority of whom failed prior T-P vancomycin treatment. Sustained clinical response rates at 30 and 90 days were 74% (34/46) and 61% (28/46). T-P fidaxomicin shows promise for management of mrCDI.

Topics & Concepts

FidaxomicinClostridioidesMedicineRegimenInternal medicineC difficileVancomycinGastroenterologySurgeryAntibioticsClostridium difficileMicrobiologyBacteriaBiologyGeneticsStaphylococcus aureusClostridium difficile and Clostridium perfringens researchMicroscopic ColitisHelicobacter pylori-related gastroenterology studies